TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8173698

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 1208

Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 1208
Study: 3524923

Group type: EXPERIMENTAL
Intervention: Steroid and chlorambucil for six months
Number of subjects: 25
Study: 1091124

Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 0
Study: 31035080

Group type: EXPERIMENTAL
Intervention: Negative affect condition
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Cigarette cue condition
Number of subjects: 174

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Overall momentary quit motivation
Number of subjects: 174
Study: 28544202

Group type: EXPERIMENTAL
Intervention: Seated arm ergometry every 30 minutes
Number of subjects: 13

Group type: COMPARATOR
Intervention: Prolonged sitting only
Number of subjects: 13
Study: 27101669

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) and standardized treatment (glucocorticoid nasal spray)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standardized treatment (glucocorticoid nasal spray)
Number of subjects: 36
Study: 23815304

Group type: EXPERIMENTAL
Intervention: Psychoeducational computer-based treatment
Number of subjects: 25
Study: 21775530

Group type: EXPERIMENTAL
Intervention: High protein, high dairy (HPHD)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adequate protein, medium dairy (APMD)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adequate protein, low dairy (APLD)
Number of subjects: 90

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 90
Study: 19480669

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 18043146

Group type: EXPERIMENTAL
Intervention: Processed PRBC (P group, n = 8)
Number of subjects: 16
Study: 14680996

Group type: EXPERIMENTAL
Intervention: Upper respiratory tract illnesses (URTIs)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study: 11731751

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 30
Study: 9230790

Group type: EXPERIMENTAL
Intervention: Oral artemether (500 mg over five days)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Oral artemether (750 mg over seven days)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Sequential treatment of oral artemether (600 mg) followed by mefloquine (1,250 mg)
Number of subjects: 151

Group type: COMPARATOR
Intervention: All groups (I, II, III)
Number of subjects: 151
Study: 8219859

Group type: EXPERIMENTAL
Intervention: Pyridoxine treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3319349

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg b.i.d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sulindac (200 mg b.i.d.)
Number of subjects: 10
Study: 29234943

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Traditional Care
Number of subjects: 119
Study: 27599227

Group type: EXPERIMENTAL
Intervention: Marriage Checkup adapted for independent practice (MC‐P)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Waitlist condition (WL)
Number of subjects: 233
Study: 25301881

Group type: EXPERIMENTAL
Intervention: Standard automated perimetry (SAP) in OSA patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (age-matched healthy individuals)
Number of subjects: 80
Study: 23423595

Group type: EXPERIMENTAL
Intervention: Compression gloves
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group without compression treatment
Number of subjects: 57
Study: 20722471

Group type: EXPERIMENTAL
Intervention: Yoga intervention (60 minutes, 3 times a week for 12 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Walking intervention (60 minutes, 3 times a week for 12 weeks)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 34
Study: 19140648

Group type: EXPERIMENTAL
Intervention: Real-time strategy video game training for 23.5 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16819378

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral family intervention with standard pediatric care
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard pediatric care
Number of subjects: 32
Study: 15504185

Group type: EXPERIMENTAL
Intervention: Ketobemidone (1 mg ml(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine (1 mg ml(‐1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketobemidone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 60
Study: 11128732

Group type: EXPERIMENTAL
Intervention: Expert physiotherapists measuring post-stroke shoulder pain using 100 mm vertical visual analogue scales (VAS) for intensity, frequency, and affective response.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Expert physiotherapists measuring site-of-pain using a categorical site-of-pain scale.
Number of subjects: 33
Study: 9139098

Group type: EXPERIMENTAL
Intervention: Medial placement of the patellar component on the medial two thirds of the patellar bone.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Centrally placed patellar component.
Number of subjects: 62
Study: 8362431

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (no warfarin)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (aspirin therapy)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (no aspirin therapy)
Number of subjects: 125
Study: 2869952

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg to 60 mg once daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acebutolol (200 mg to 600 mg once daily)
Number of subjects: 40
Study: 30532522

Group type: EXPERIMENTAL
Intervention: Group-based health promotion program with a person-centered approach (4 weeks of group intervention and one follow-up home visit)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Group-based health promotion program with a person-centered approach
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (no intervention but access to ordinary health care services)
Number of subjects: 131
Study: 27454540

Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Interlaminar Discectomy (PEID)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Percutaneous Endoscopic Transforaminal Discectomy (PETD)
Number of subjects: 60
Study: 24657310

Group type: EXPERIMENTAL
Intervention: Family-based exposure/response prevention therapy (E/RP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 31
Study: 22565936

Group type: EXPERIMENTAL
Intervention: Pacemaker ON (dual-chamber pacing with rate drop response)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Pacemaker OFF (sensing only)
Number of subjects: 89
Study: 21104944

Group type: EXPERIMENTAL
Intervention: Capsaicin cream 0.05% (Finalgon® CPDWärmecreme)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 18182416

Group type: EXPERIMENTAL
Intervention: Nabilone (2 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Dihydrocodeine (240 mg)
Number of subjects: 96
Study: 16095893

Group type: EXPERIMENTAL
Intervention: Nebulized sodium cromoglycate (3-4 times/day)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Nebulized sodium cromoglycate (3-4 times/day) in atopic patients
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group (Isotonic saline)
Number of subjects: 251
Study: 12969694

Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogen alone or with alendronate
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen alone or with alendronate
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Hormone therapy alone
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Hormone therapy plus alendronate
Number of subjects: 173
Study: 10655861

Group type: EXPERIMENTAL
Intervention: Hydrocellular dressing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydrocolloid dressing
Number of subjects: 40
Study: 8542129

Group type: EXPERIMENTAL
Intervention: NCPAP
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study: 1905509

Group type: EXPERIMENTAL
Intervention: GH/hMG/hCG
Number of subjects: 7

Group type: COMPARATOR
Intervention: hMG/hCG
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: GH/hMG
Number of subjects: 7
Study: 6221247

Group type: EXPERIMENTAL
Intervention: Prednisone 1 mg/kg/24 h for one month, then decreasing dosage; cyclophosphamide 2 mg/kg/24 h if failure at one month
Number of subjects: 14

Group type: COMPARATOR
Intervention: Prednisone with 3 plasma exchanges over a 10-day period, continued weekly if required
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study: 30644108

Group type: EXPERIMENTAL
Intervention: Adolescent Depression Awareness Program (ADAP)
Number of subjects: 1427

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1427
Study: 29952046

Group type: EXPERIMENTAL
Intervention: Perceived relationship to health care provider
Number of subjects: 187
Study: 27071963

Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (zona thinning)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (no laser-assisted hatching)
Number of subjects: 178
Study: 24518158

Group type: EXPERIMENTAL
Intervention: T‐cell depleting induction therapy
Number of subjects: 306
Study: 21383687

Group type: EXPERIMENTAL
Intervention: cGVHD
Number of subjects: 12

Group type: COMPARATOR
Intervention: SS
Number of subjects: 12

Group type: COMPARATOR
Intervention: MGD
Number of subjects: 12
Study: 20394851

Group type: EXPERIMENTAL
Intervention: Continuous, hyperfractionated, accelerated radiotherapy (CHART)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT)
Number of subjects: 918
Study: 17397735

Group type: EXPERIMENTAL
Intervention: Primary posterior continuous curvilinear capsulorhexis (PCCC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No primary posterior continuous curvilinear capsulorhexis (non-PCCC)
Number of subjects: 52
Study: 16277026

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Single oestrogen
Number of subjects: 2
Study: 12144587

Group type: EXPERIMENTAL
Intervention: Alosetron (1-4 mg b.d.)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Alosetron
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 10574305

Group type: EXPERIMENTAL
Intervention: Milkshake preload
Number of subjects: 58

Group type: COMPARATOR
Intervention: No preload
Number of subjects: 58
Study: 8653184

Group type: EXPERIMENTAL
Intervention: Disclosure method of service delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-disclosure method of service delivery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-test result values with prompts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-test result values without prompts
Number of subjects: 0
Study: 2354600

Group type: EXPERIMENTAL
Intervention: Cleansing water enema followed by DCBE at 15 minutes
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cleansing water enema followed by DCBE at 30 minutes
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cleansing water enema followed by DCBE at 45 minutes
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cleansing water enema followed by DCBE at 60 minutes
Number of subjects: 59
Study: 7378008

Group type: EXPERIMENTAL
Intervention: 0.02% naphazoline hydrochloride
Number of subjects: 6

Group type: COMPARATOR
Intervention: Other nonprescription decongestant preparations
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Higher concentrations of naphazoline
Number of subjects: 6
Study: 31600032

Group type: EXPERIMENTAL
Intervention: Juvenile Arthritis (JA)
Number of subjects: 232
Study: 27816940

Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment (mean daily dose: 18.1 mg)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Naturalistic observation (nonmedicated group)
Number of subjects: 203
Study: 26606435

Group type: EXPERIMENTAL
Intervention: HYC‐24L (24 mg/mL of hyaluronic acid, 0.3% lidocaine)
Number of subjects: 136

Group type: COMPARATOR
Intervention: CPM‐22.5 (22.5 mg/mL of hyaluronic acid)
Number of subjects: 136
Study: 24338168

Group type: EXPERIMENTAL
Intervention: Low-dose gemcitabine (250 mg/m(2)) 6-h infusion on days 1 and 8, and cisplatin (70 mg/m(2)) on day 2 every 21-day cycle (arm 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Standard-dose gemcitabine (1,250 mg/m(2)) 30-min infusion on days 1 and 8, with the same dose of cisplatin (arm 2)
Number of subjects: 120
Study: 22717496

Group type: EXPERIMENTAL
Intervention: Vocal Function Exercise (VFE) program
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 19204651

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) paroxetine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17458644

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg IV (group O)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: lornoxicam 8 mg IV (group L)
Number of subjects: 108

Group type: COMPARATOR
Intervention: normal saline 2 ml IV (group P)
Number of subjects: 108
Study: 15700725

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg plus zolpidem 0 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg plus melatonin 0 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Melatonin 0 mg plus zolpidem 0 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg alone
Number of subjects: 80
Study: 11993610

Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Number of subjects: 1153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1153
Study: 9535248

Group type: EXPERIMENTAL
Intervention: PncD vaccine (1, 3, or 10 microg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Polysaccharide vaccine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PncD vaccine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (physiologic saline)
Number of subjects: 75
Study: 7733474

Group type: EXPERIMENTAL
Intervention: yrIL‐2 (1,000,000 U per 0.1 m2 body surface)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: yrIL‐2 added to therapeutic complex
Number of subjects: 17
Study: 2645503

Group type: EXPERIMENTAL
Intervention: 50 mg nandrolone decanoate (ND) intramuscularly every 3 weeks for 1 year
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo injections every 3 weeks for 1 year
Number of subjects: 39
Study: 31197540

Group type: EXPERIMENTAL
Intervention: P-COCC
Number of subjects: 98

Group type: COMPARATOR
Intervention: Video
Number of subjects: 98

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 98
Study: 30351995

Group type: EXPERIMENTAL
Intervention: Micro-incision (2.25 mm)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Small-incision (2.75 mm)
Number of subjects: 67
Study: 28045314

Group type: EXPERIMENTAL
Intervention: CPP‐ACP paste (GC Tooth Mousse) applied at each monthly orthodontic follow‐up examination
Number of subjects: 57

Group type: COMPARATOR
Intervention: Routine orthodontic treatment (control group)
Number of subjects: 57
Study: 25590146

Group type: EXPERIMENTAL
Intervention: Counseling to caregivers and classroom health education interventions
Number of subjects: 65

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 65
Study: 23663810

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 980
Study: 20215772

Group type: EXPERIMENTAL
Intervention: Biohormon (somatropin from transgenic cows)
Number of subjects: 24

Group type: COMPARATOR
Intervention: HHT (somatropin from E. coli)
Number of subjects: 24
Study: 18362870

Group type: EXPERIMENTAL
Intervention: Bupropion XL (150 to 300 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Escitalopram (10 to 20 mg/day)
Number of subjects: 24
Study: 17050258

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls (matched group)
Number of subjects: 30
Study: 12725705

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 2 mg twice daily (R4 + SU)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg twice daily (R8 + SU)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo (SU + P)
Number of subjects: 530
Study: 11221822

Group type: EXPERIMENTAL
Intervention: $5 incentive
Number of subjects: 1800

Group type: COMPARATOR
Intervention: $2 incentive
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Follow-up phone calls
Number of subjects: 1800
Study: 9043007

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg four times daily
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg four times daily
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg twice daily
Number of subjects: 452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Tramadol groups
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 452
Study: 21207909

Group type: EXPERIMENTAL
Intervention: Personal approach video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Factual approach video
Number of subjects: 0
Study: 3365580

Group type: EXPERIMENTAL
Intervention: CPSC data provided to medical personnel
Number of subjects: 4

Group type: COMPARATOR
Intervention: No CPSC data provided to medical personnel
Number of subjects: 4
Study: 29526707

Group type: EXPERIMENTAL
Intervention: Self-administered DMPA-SC
Number of subjects: 731

Group type: COMPARATOR
Intervention: Provider-administered DMPA-SC
Number of subjects: 731
Study: 28062255

Group type: EXPERIMENTAL
Intervention: Bihemispheric tDCS (anodal over left temporal area and cathodal over right temporal area)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Unihemispheric anodal tDCS over the left temporal area
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 30
Study: 25725185

Group type: EXPERIMENTAL
Intervention: Oil-massage
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Massage alone
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control
Number of subjects: 121
Study: 23377641

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention for anxiety disorders
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control group (higher-income participants)
Number of subjects: 287
Study: 21471653

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 81
Study: 17404739

Group type: EXPERIMENTAL
Intervention: Regimen A: four doses of 20 ml 40% w/v barium sulphate
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Regimen B: three doses of 20 ml 40% w/v barium sulphate
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Regimen C: three doses of 20 ml 40% w/v barium sulphate plus 220 ml 2.1% barium sulphate
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Regimen D: three doses of 20 ml 40% w/v barium sulphate plus 15 ml diatriazoate megluamine
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Reduced-laxative CTC
Number of subjects: 95
Study: 16842476

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 130

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 130
Study: 14666441

Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (SN)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no hypotension)
Number of subjects: 45
Study: 15470825

Group type: EXPERIMENTAL
Intervention: L-threodops (200 mg orally 2 hours before each session) with physical therapy (PT) and occupational therapy (OT) for 2 months, 3 days a week.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group received PT and OT for 4 months without L-threodops.
Number of subjects: 13
Study: 9509823

Group type: EXPERIMENTAL
Intervention: Diet plus aerobic exercise program in a supervised group setting (Group B)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Diet plus weight training plus aerobic exercise program (Group D)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Diet alone (Group A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Diet plus weight training (Group C)
Number of subjects: 31
Study: 29556709

Group type: EXPERIMENTAL
Intervention: 11+ injury prevention program (High Compliance, > 40 doses/season)
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: 11+ injury prevention program (Moderate Compliance, 20-39 doses/season)
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: 11+ injury prevention program (Low Compliance, 1-19 doses/season)
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Compliance as a continuous variable
Number of subjects: 675
Study: 26476719

Group type: EXPERIMENTAL
Intervention: Morphine (20 mg/10 ml)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ketamine (50 mg + morphine 10 mg/10 ml)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline (0.9 % 10 ml)
Number of subjects: 45
Study: 24852042

Group type: EXPERIMENTAL
Intervention: Guselkumab (various doses)
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 or 90 mg
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1047
Study: 21870975

Group type: EXPERIMENTAL
Intervention: SCTG with surgical microscope
Number of subjects: 24

Group type: COMPARATOR
Intervention: SCTG without surgical microscope
Number of subjects: 24
Study: 19874691

Group type: EXPERIMENTAL
Intervention: Standard treatment + Glutamine 10g tid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 60
Study: 16373408

Group type: EXPERIMENTAL
Intervention: Body temperature contrast medium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Room temperature contrast medium
Number of subjects: 0
Study: 15373927

Group type: EXPERIMENTAL
Intervention: Desmopressin (2 microg intravenous dose)
Number of subjects: 24
Study: 11772354

Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy of artemether and praziquantel
Number of subjects: 0